This Month in JNM

January 2, 2018

Hot Topics: ORBITA endpointsDilsizian and Erario offer a critical review of primary and secondary endpoints in the Percutaneous Coronary Intervention in Stable Angina clinical trial. Page 1

FEATURED ARTICLE OF THE MONTH: The State of the Art: Maximizing total-body PET –  Cherry and colleagues discuss their efforts to develop and apply a first-generation total-body PET/CT scanner, the benefits of increasing body coverage, and likely clinical results of improvements in time-of-flight PET. Page 3 

Editorial: Challenging nuclear cardiology research Dilsizian comments on ways to increase the relevance of research in all areas of nuclear cardiology, with a special focus on factors currently limiting progression to routine clinical use. Page 13

Immune patterns of response in HLDercle and colleagues investigate 3-month 18F-FDG PET/CT for identification of patients with Hodgkin lymphoma responding to immune-checkpoint blockade by anti–programmed death 1 antibodies and describe new immune response and progression patterns. Page 15

18F-FDG PET/CT in pediatric osteosarcoma Davis and colleagues explore the relationship of 18F-FDG uptake in primary tumor at diagnosis, during therapy, and after therapy with histologic response and event-free survival in pediatric and young adult patients with osteosarcoma. Page 25

18F-FDG PET and gene networksNa and Choi identify and investigate gene networks associated with tumor metabolism and their biologic function, using RNA sequencing and 18F-FDG PET data. Page 31

64Cu-trastuzumab uptake in breast cancerMortimer and colleagues characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab on PET/CT and standard immunohistochemistry-based classification of human epidermal growth factor receptor 2 status in women with metastatic breast cancer. Page 38

FMT/CT and PET/MR imagingHage and colleagues compare in squamous cell carcinoma xenografts the performances of advanced fluorescence-mediated tomography/CT and PET/MR imaging in quantitative assessment of biodistributions of different antibody formats and their dependence on specific labels. Page 44

89Zr-transferrin vs. 18F-FDG PET in TNBCHenry and colleagues compare 89Zr-transferrin and 18F-FDG PET imaging in vitro and in preclinical models of triple-negative breast cancer, with a focus on the ability of 89Zr-transferrin to identify expression of the MYC oncogene. Page 51

Cerenkov-activated taggingDas and colleagues describe research on a strategy to enable targeted Cerenkov luminescence–activated drug delivery to cancer cells and report on a tagging method for associated fluorescence imaging. Page 58

Special Contribution: AUC for SSTR PETRepresentatives from 9 nuclear medicine, imaging, and oncology organizations provide consensus appropriate use criteria intended for referring medical practitioners on the use of somatostatin receptor PET in patients with neuroendocrine tumors. Page 66

Single-sample dosimetry after 177Lu-DOTA Hänscheid and colleagues describe a method for dosimetry simplification in 177Lu-DOTATATE/DOTATOC therapy, allowing calculation of absorbed doses from a single SPECT/CT assessment of abdominal activity distribution 4 days after treatment. Page 75

68Ga-PSMA PET/CT and PC management Roach and colleagues report on the results of an Australian multicenter study assessing whether 68Ga-prostate-specific membrane antigen PET/CT imaging affects management intent in patients with primary and/or recurrent prostate cancer. Page 82

Management after 68Ga-PSMA PET/CT Afaq and a team of international researchers detail the impact of 68Ga-prostate-specific membrane antigen PET/CT on management of prostate cancer in patients with biochemical recurrence. Page 89

Radionuclide targeting with ADAPT Lindbo and colleagues determine whether the use of a nonresidualizing label or different label placement improves the targeting properties of albumin-binding domain–derived affinity scaffold protein-6, a tracer for human epidermal growth factor receptor 2 expression. Page 93

Hypercapnia and MBF Pelletier-Galarneau and colleagues document the pharmacodynamics of CO2 for myocardial blood flow using prospective end-tidal targeting to precisely control arterial Pco2 and PET to assess myocardial blood flow. Page 100

Pseudoreference regions for 11C-PBR28 PET Albrecht and colleagues evaluate various ratio approaches for translocator protein PET imaging and compare these with standard kinetic modeling techniques in patients with chronic low back pain or amyotrophic lateral sclerosis and healthy controls. Page 107

Off-target labeling of AV-1451 Barrio provides perspective on the rapid adoption of this agent for tau imaging with PET, reviews reports that it is less than ideal for clinical applications, and previews a related article in this issue of JNM. Page 115

18F-AV-1451 and iron Choi and colleagues investigate the relationship between 18F-AV-1451 off-target binding in the basal ganglia of elderly patients on PET and iron accumulation using iron-sensitive R2* MR imaging. Page 117

Thyroid stunning by contrast agents Vassaux and colleagues ask whether it is the free iodide in iodinated imaging contrast media or the media themselves that reduce thyroid uptake on diagnostic thyroid scintigraphy and complicate radioiodine treatment of thyroid malignancies. Page 121

PET/CT in chronic Q fever Kouijzer and colleagues from multiple Dutch research sites explore the diagnostic, management, and prognostic value of 18F-FDG PET/CT in chronic Q fever at diagnosis and during follow-up. Page 127

FEATURED BASIC SCIENCE ARTICLE: Imaging bacterial infection with 18F-FDS Li and colleagues validate 2-18F-fluorodeoxysorbitol as a potential radiopharmaceutical for longitudinal imaging bacterial infection and differentiating K. pneumoniae lung infection from inflammation. Page 134

First KOR PET 18F tracer Li and colleagues synthesize and evaluate 18F-LY2459989, a k-opioid receptor–antagonist radiotracer, in nonhuman primates and compare it with 11C-LY2459989. Page 140

FEATURED CLINICAL INVESTIGATION ARTICLE: 18F-MFBG imaging of neuroendocrine cancerPandit-Taskar and colleagues report on a first-in-human study of 18F-meta-fluorobenzylguanidine PET imaging to evaluate its safety, feasibility, pharmacokinetics, and dosimetry in patients with neuroendocrine tumors. Page 147

OLINDA/EXM 2.0 compendium Stabin and Siegel present a compendium of about 100 radiopharmaceuticals, based on the OLINDA/EXM version 2.0 software and using a new generation of voxel-based, realistic human computational phantoms to develop dose estimates. Page 154

89Zr-trastuzumab in esophagogastric cancer O’Donoghue and colleagues evaluate the safety, pharmacokinetics, biodistribution, and dosimetry of 89Zr-trastuzumab in human epidermal growth factor receptor 2–positive esophagogastric adenocarcinoma. Page 161

PET stability during aggressive MR Deller and colleagues test the PET stability of a whole-body PET/MR system during simultaneous scanning of intensive MR pulse sequences, with resulting promise for demanding applications such as kinetic modeling. Page 167